{"title_page": "Irampanel", "text_new": "{{Drugbox\n| IUPAC_name        = ''N'',''N''-Dimethyl-2-[2-(3-phenyl-1,2,4-oxadiazol-5-yl)phenoxy]ethanamine\n| image             = Irampanel.svg\n| CAS_number        = 206260-33-5\n| UNII_Ref = {{fdacite|correct|FDA}}\n| UNII = R2GZD7LMYX\n| ATC_prefix        = None\n| ATC_suffix        = \n| PubChem           = 3038472\n| DrugBank          = \n| ChEMBL = 29741\n| ChemSpiderID      = 2302037\n| C=18 | H=19 | N=3 | O=2\n| molecular_weight  = 309.362 g/mol\n| smiles            = CN(C)CCOc1ccccc1c2nc(no2)c3ccccc3\n| StdInChI          = 1S/C18H19N3O2/c1-21(2)12-13-22-16-11-7-6-10-15(16)18-19-17(20-23-18)14-8-4-3-5-9-14/h3-11H,12-13H2,1-2H3\n| StdInChIKey       = QZULPCPLWGCGSL-UHFFFAOYSA-N\n| bioavailability   = \n| protein_bound     = \n| metabolism        = \n| elimination_half-life = \n| excretion         = \n| pregnancy_AU      =  <!-- A / B1 / B2 / B3 / C / D / X -->\n| pregnancy_US      =  <!-- A / B            / C / D / X -->\n| pregnancy_category=  \n| legal_AU =  <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->\n| legal_CA =  <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->\n| legal_UK =  <!-- GSL, P, POM, CD, or Class A, B, C -->\n| legal_US =  <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->\n| legal_status      = \n| routes_of_administration = \n}}\n\n'''Irampanel''' ([[International Nonproprietary Name|INN]], code name '''BIIR-561''') is a [[drug]] which acts as a dual [[noncompetitive antagonist]] of the [[AMPA receptor]] and [[sodium channel blocker|neuronal voltage-gated sodium channel blocker]].<ref name=\"pmid12137411\">{{cite journal | author = Feigin V | title = Irampanel Boehringer Ingelheim | journal = Curr Opin Investig Drugs | volume = 3 | issue = 6 | pages = 908\u201310 |date=June 2002  | pmid = 12137411 | doi = | url = }}</ref><ref name=\"pmid17102687\">{{cite journal |vauthors=Wang KK, Larner SF, Robinson G, Hayes RL | title = Neuroprotection targets after traumatic brain injury | journal = Curr. Opin. Neurol. | volume = 19 | issue = 6 | pages = 514\u20139 |date=December 2006  | pmid = 17102687 | doi = 10.1097/WCO.0b013e3280102b10|url=https://zenodo.org/record/895687}}</ref> It was under development by [[Boehringer Ingelheim]] for the treatment of [[acute stroke]]/[[cerebral ischemia]] but never completed clinical trials for this indication.<ref name=\"Gulati2007\">{{cite book|author1=Arunabha Ray |author2=Kavita Gulati |title=Current Trends in Pharmacology|url=https://books.google.com/books?id=uB2vWIQBbxoC&pg=PA321|date=1 January 2007|publisher=I. K. International Pvt Ltd|isbn=978-81-88237-77-7|pages=321\u2013}}</ref><ref name=\"pmid15857300\">{{cite journal | author = Weiser T | title = AMPA receptor antagonists for the treatment of stroke | journal = Curr Drug Targets CNS Neurol Disord | volume = 4 | issue = 2 | pages = 153\u20139 |date=April 2005  | pmid = 15857300 | doi = | url = http://openurl.ingenta.com/content/nlm?genre=article&issn=1568-007X&volume=4&issue=2&spage=153&aulast=Weiser}}</ref> Irampanel was also trialed, originally, for the treatment of [[epilepsy]] and [[pain]], but these indications, too, were abandoned,<ref name=\"pmid12137411\" /> and the drug was ultimately never marketed.\n\n==References==\n{{Reflist|2}}\n\n{{Anticonvulsants}}\n{{Ion channel modulators}}\n{{Ionotropic glutamate receptor modulators}}\n\n[[Category:AMPA receptor antagonists]]\n[[Category:Anticonvulsants]]\n[[Category:Neuroprotective agents]]\n[[Category:Oxadiazoles]]\n[[Category:Sodium channel blockers]]\n[[Category:Abandoned drugs]]\n\n\n{{anticonvulsant-stub}}\n", "text_old": "{{Drugbox\n| IUPAC_name        = ''N'',''N''-Dimethyl-2-[2-(3-phenyl-1,2,4-oxadiazol-5-yl)phenoxy]ethanamine\n| image             = Irampanel.svg\n| CAS_number        = 206260-33-5\n| ATC_prefix        = None\n| ATC_suffix        = \n| PubChem           = 3038472\n| DrugBank          = \n| ChEMBL = 29741\n| ChemSpiderID      = 2302037\n| C=18 | H=19 | N=3 | O=2\n| molecular_weight  = 309.362 g/mol\n| smiles            = CN(C)CCOc1ccccc1c2nc(no2)c3ccccc3\n| StdInChI          = 1S/C18H19N3O2/c1-21(2)12-13-22-16-11-7-6-10-15(16)18-19-17(20-23-18)14-8-4-3-5-9-14/h3-11H,12-13H2,1-2H3\n| StdInChIKey       = QZULPCPLWGCGSL-UHFFFAOYSA-N\n| bioavailability   = \n| protein_bound     = \n| metabolism        = \n| elimination_half-life = \n| excretion         = \n| pregnancy_AU      =  <!-- A / B1 / B2 / B3 / C / D / X -->\n| pregnancy_US      =  <!-- A / B            / C / D / X -->\n| pregnancy_category=  \n| legal_AU =  <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->\n| legal_CA =  <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->\n| legal_UK =  <!-- GSL, P, POM, CD, or Class A, B, C -->\n| legal_US =  <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->\n| legal_status      = \n| routes_of_administration = \n}}\n\n'''Irampanel''' ([[International Nonproprietary Name|INN]], code name '''BIIR-561''') is a [[drug]] which acts as a dual [[noncompetitive antagonist]] of the [[AMPA receptor]] and [[sodium channel blocker|neuronal voltage-gated sodium channel blocker]].<ref name=\"pmid12137411\">{{cite journal | author = Feigin V | title = Irampanel Boehringer Ingelheim | journal = Curr Opin Investig Drugs | volume = 3 | issue = 6 | pages = 908\u201310 |date=June 2002  | pmid = 12137411 | doi = | url = }}</ref><ref name=\"pmid17102687\">{{cite journal |vauthors=Wang KK, Larner SF, Robinson G, Hayes RL | title = Neuroprotection targets after traumatic brain injury | journal = Curr. Opin. Neurol. | volume = 19 | issue = 6 | pages = 514\u20139 |date=December 2006  | pmid = 17102687 | doi = 10.1097/WCO.0b013e3280102b10|url=https://zenodo.org/record/895687}}</ref> It was under development by [[Boehringer Ingelheim]] for the treatment of [[acute stroke]]/[[cerebral ischemia]] but never completed clinical trials for this indication.<ref name=\"Gulati2007\">{{cite book|author1=Arunabha Ray |author2=Kavita Gulati |title=Current Trends in Pharmacology|url=https://books.google.com/books?id=uB2vWIQBbxoC&pg=PA321|date=1 January 2007|publisher=I. K. International Pvt Ltd|isbn=978-81-88237-77-7|pages=321\u2013}}</ref><ref name=\"pmid15857300\">{{cite journal | author = Weiser T | title = AMPA receptor antagonists for the treatment of stroke | journal = Curr Drug Targets CNS Neurol Disord | volume = 4 | issue = 2 | pages = 153\u20139 |date=April 2005  | pmid = 15857300 | doi = | url = http://openurl.ingenta.com/content/nlm?genre=article&issn=1568-007X&volume=4&issue=2&spage=153&aulast=Weiser}}</ref> Irampanel was also trialed, originally, for the treatment of [[epilepsy]] and [[pain]], but these indications, too, were abandoned,<ref name=\"pmid12137411\" /> and the drug was ultimately never marketed.\n\n==References==\n{{Reflist|2}}\n\n{{Anticonvulsants}}\n{{Ion channel modulators}}\n{{Ionotropic glutamate receptor modulators}}\n\n[[Category:AMPA receptor antagonists]]\n[[Category:Anticonvulsants]]\n[[Category:Neuroprotective agents]]\n[[Category:Oxadiazoles]]\n[[Category:Sodium channel blockers]]\n[[Category:Abandoned drugs]]\n\n\n{{anticonvulsant-stub}}\n", "name_user": "Fswitzer4", "label": "safe", "comment": "added FDA UNII to drug box", "url_page": "//en.wikipedia.org/wiki/Irampanel"}
